What Does Embera NeuroTherapeutics Do?

Total employees10
HeadquartersBoston
Founded2004

Embera NeuroTherapeutics, Inc. is a specialized clinical-stage biopharmaceutical company dedicated to creating and advancing new treatments for a wide array of addictions and substance use disorders (SUDs). Their primary drug candidate, EMB-001, is a unique patented combination of two existing FDA-approved medications, metyrapone and oxazepam. This formulation is engineered to modulate the body's stress response system, which plays a critical role in the cycle of addiction. By targeting the neurobiological mechanisms that drive cravings and relapse, Embera aims to offer effective solutions for individuals grappling with conditions such as cocaine use disorder, tobacco addiction, and potentially other forms of addiction, addressing significant unmet medical needs.

Where Is Embera NeuroTherapeutics's Headquarters?

HQ Function

The Boston headquarters manages corporate administration, strategic planning, business development, clinical trial oversight, and investor relations. This location leverages the rich biotech ecosystem for partnerships, talent, and funding.

Notable Features:

Situated within BioLabs, a state-of-the-art shared laboratory and office facility tailored for life science startups. This provides access to advanced shared equipment, valuable networking opportunities, and a collaborative R&D environment.

Work Culture:

As a clinical-stage biopharmaceutical company, Embera fosters a dynamic, science-driven, and mission-oriented work culture. There is a strong emphasis on collaboration, innovation, and achieving critical clinical milestones to bring new addiction treatments to patients.

HQ Significance:

The Boston-area headquarters provides crucial access to a dense network of world-class research institutions, a skilled talent pool, venture capital, and pharmaceutical partners essential for a biotech company's growth. The Shreveport research operations are vital for the company's core R&D activities.

Values Reflected in HQ: The headquarters' choice reflects values of innovation, collaboration, efficiency, and a strong commitment to scientific advancement in the field of addiction treatment.

Location:

While Embera NeuroTherapeutics is primarily based in the United States with corporate functions in Boston, MA, and research operations in Shreveport, LA, its impact is global. The development of its addiction treatments, such as EMB-001, often involves multi-site clinical trials that may include international locations to ensure diverse patient populations and satisfy global regulatory standards. The company actively engages with the international scientific and medical communities through publications, conferences, and collaborations to further the understanding and treatment of substance use disorders worldwide.

Street Address:

c/o BioLabs at The Link, 1350 Boylston Street, Suite B2

City:

Boston

State/Province:

MA

Country:

USA

Where Else Does Embera NeuroTherapeutics Operate Around the World?

Shreveport, Louisiana, USA

Address: Specific street address for Shreveport research operations not publicly detailed; operations are centered in this region.

The Shreveport site leverages regional research infrastructure, collaborations with local academic institutions, and specialized talent to advance the company's scientific programs and drug development efforts.

Buying Intent Signals for Embera NeuroTherapeutics

Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.

Notable news
Hiring actively
Corporate Finance
Corporate Finance
Corporate Finance
Corporate Finance
Corporate Finance
*Example signal, not calculated in real time

Who's Leading Embera NeuroTherapeutics? Meet the Executive Team

As of April 2025, Embera NeuroTherapeutics' leadership includes:

Robert (Bob) A. Linke, Jr., MBA - President & Chief Executive Officer
Michael J. Detke, MD, PhD - Chief Medical Officer
Louis D. Scampavia, PhD - Head of Chemistry, Manufacturing and Controls (CMC)
Tracey A. G. C. du Laney, MD, MPH, FACP, FACMT - Medical Director

Who's Investing in Embera NeuroTherapeutics?

Embera NeuroTherapeutics has been backed by several prominent investors over the years, including:

National Institute on Drug Abuse (NIDA) (significant grant funding)
National Institute on Alcohol Abuse and Alcoholism (NIAAA) (grant funding)
Various private equity firms
Venture capital groups
Angel investors

What Leadership Changes Has Embera NeuroTherapeutics Seen Recently?

Hire0
Exits0

Based on publicly available information and company announcements over the last 12 months, there have been no major new hires or departures at the executive level for Embera NeuroTherapeutics. The leadership team appears to be stable, continuing to guide the company's clinical development programs.

What Technology (Tech Stack) Is Used byEmbera NeuroTherapeutics?

Discover the tools Embera NeuroTherapeutics uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.

Embera NeuroTherapeutics Email Formats and Examples

Embera NeuroTherapeutics typically uses a standard professional email format common in the biopharmaceutical industry. The most prevalent format combines the first initial of an employee's name with their last name.

[first_initial][last]@emberaneuro.com

Format

rlinke@emberaneuro.com

Example

85%

Success rate

What's the Latest News About Embera NeuroTherapeutics?

PR NewswireMarch 20, 2024

Embera NeuroTherapeutics Announces EMB-001 Significantly Reduced Tobacco Use in Patients with Co-Occurring Tobacco Use Disorder and Schizophrenia Spectrum Disorders in an Investigator-Initiated Trial

Embera reported positive findings from an investigator-initiated trial where EMB-001 showed a significant reduction in tobacco consumption among patients diagnosed with both tobacco use disorder and schizophrenia spectrum disorders. This study underscores EMB-001's potential to treat addiction in complex patient groups....more

PR NewswireOctober 4, 2023

Embera NeuroTherapeutics to Present at the ECNP Congress 2023 on EMB-001 for the Treatment of Substance Use Disorders

Embera NeuroTherapeutics announced its upcoming presentation on its lead candidate EMB-001 at the European College of Neuropsychopharmacology (ECNP) Congress. The company shared data and insights from its ongoing research into treatments for substance use disorders....more

GlobeNewswireMay 23, 2023

Embera NeuroTherapeutics Announces Last Patient Completes Last Visit in Phase 2a Study of EMB-001 in Smoking Cessation for Patients with Schizophrenia

The company marked a significant clinical milestone with the announcement that the last patient had completed their final visit in the Phase 2a study of EMB-001. This trial assessed the drug's efficacy for smoking cessation in individuals diagnosed with schizophrenia....more

Highperformr's free tools for company research

Explore Employees by Region or Country

See where a company’s workforce is located, by country or region.

View Funding Details

View past and recent funding rounds with amounts and investors.

Understand Revenue Insights

Understand company revenue estimates and financial scale.

Track Active Job Openings

Track active roles and hiring trends to spot growth signals.

Review Product and Offerings

Discover what a company offers—products, platforms, and solutions.

Get SIC or NAICS Codes

Get the company’s official SIC and NAICS classifications.

Analyze Website Traffic Trends

Analyze visitor volume, engagement, and top traffic sources.

Discover Social Profiles and Engagement

Explore LinkedIn, Twitter, and other active social profiles.

Identify Top Competitors

Identify top competitors based on similar business traits.

Research and Discover Companies with Highperformr — Smarter, Faster

Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.

Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.

  • Track intent signals to find buyers who are actively in-market
  • Enrich contacts and companies instantly, no need to switch tools
  • Automate workflows to stay ahead of every change
  • Connect your CRM & tools for seamless data sync and activation

Thousands of companies, including Embera NeuroTherapeutics, are just a search away.